Cutaneous Leishmaniasis. Cutaneous leishmaniasis
Conditions
Interventions
Intervention 1: Group (A) was treated with (MA) 60 mg/kg/day/IM and oral placebo. Intervention 2: Group (B) received (MA) 30 mg/kg/day/IM and oral Cimetidine 1200 mg/day. Intervention 3: Group (C) rec
Treatment - Drugs
Group (A) was treated with (MA) 60 mg/kg/day/IM and oral placebo.
Group (B) received (MA) 30 mg/kg/day/IM and oral Cimetidine 1200 mg/day.
Group (C) received (MA) 30 mg/kg/day/IM and oral placebo.
Sponsors
The University of Aleppo
Eligibility
Sex/Gender
All
Age
5 Years to 65 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria: parasitological confirmation; age between 5 to 65 years old; normal values of the liver, kidney, and pancreas function tests and EKG before treatment. Exclusion criteria: contraindication to use (MA); pregnant and lactating women; patients with history of cardiac, renal and hepatic diseases; those under treatment with other drugs during the month prior to commencement of the study.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Diameter of lesion. Timepoint: Every two weeks from the beginning of the trial up to six weeks and then at 8 and 12 weeks. Method of measurement: Socal Method. | — |
Secondary
| Measure | Time frame |
|---|---|
| Healing time for lesion. Timepoint: Every two weeks from the beginning of the trial up to six weeks and then at 8 and 12 weeks. Method of measurement: complete response, partial response and no response. | — |
Countries
Syrian Arab Republic
Contacts
Public ContactSiavash Mohammadzadeh Shanehsaz
Aleppo University Hospital
Outcome results
None listed